Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has requested a trading halt for its securities pending an announcement regarding a proposed underwriting agreement related to its outstanding options. The halt will remain in effect until the market opens on a specified date or until the announcement is released, whichever comes first. The company has confirmed that it is not aware of any reasons why this request should not be granted.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-866
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Half-Year Financial Report and Appendix 4D
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- ColoSTAT commercial deployment - First physician enrolled
- Rhythm Biosciences Signs Manufacturing Agreement
- Quarterly Activities Report and Appendix 4C
Later from Rhythm Biosciences
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- RHY Executes SE Asian Genetype Distribution Agreement
- NATA Accredits ColoSTAT Clinical Testing Service
- First ColoSTAT Clinical Test Sale
- Response to ASX Query Letter
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences